目的 观察艾迪注射液联合帕博利珠单抗治疗晚期非小细胞肺癌的临床疗效。方法 选取2019年1月—2022年5月在南通市海门区人民医院肿瘤内科住院治疗的120例肺癌患者，采用随机数字表法将所有患者分为对照组和治疗组，每组各60例。对照组静脉滴注帕博利珠单抗，2mg/kg，药物给药时间为30min以上，每3周给药1次。治疗组在对照组的基础上静脉滴注艾迪注射液，50mL/次，1次/d。两组均治疗6周。观察两组的临床疗效，比较两组生活质量评分（FACT-L）、卡氏功能状态量表评分（KPS）、CD3⁺、CD4⁺、CD8⁺、CD4⁺/CD8⁺及白细胞介素-6（IL-6）、血管内皮生长因子（VEGF）、转化生长因子-β₁（TGF-β₁）、γ干扰素（IFN-γ）水平。结果 治疗后，治疗组患者疾病控制率是83.33%，显著高于对照组的60.00%（P<0.05）。治疗后，治疗组咳痰、胸闷、胸痛、痰中有血缓解时间均显著短于对照组（P<0.05）。治疗后，两组患者FACT-L评分、KPS评分均较治疗前显著升高（P<0.05）；治疗后，治疗组FACT-L评分、KPS评分均高于对照组（P<0.05）。治疗后，两组CD3⁺、CD4⁺、CD4⁺/CD8⁺均较治疗前显著升高，CD8⁺显著降低（P<0.05）；治疗后，治疗组T淋巴细胞亚群指标改善优于对照组（P<0.05）。治疗后，两组患者IL-6、VEGF、TGF-β₁水平均较治疗前显著降低，而IFN-γ显著升高（P<0.05）；治疗后治疗组血清炎性因子水平改善优于对照组（P<0.05）。治疗后，治疗组不良反应发生率是6.67%，显著低于对照组的18.33%（P<0.05）。结论 艾迪注射液联合帕博利珠单抗治疗晚期非小细胞肺癌有一定疗效，可提高患者免疫功能，有效降低炎性因子水平，明显提高患者生活质量，值得推广。

Objective To investigate the clinical study of Aidi Injection combined with pembrolizumab in treatment of advanced non-small cell lung cancer. Methods A total of 120 cases of lung cancer hospitalized in the Department of Oncology of Nantong Haimen People’s Hospital from January 2019 to May 2022 were selected. All patients were divided into control group and treatment group by random number table method, with 60 cases in each group. Patients in the control group were iv administered with Pembrolizumab Injection, 2 mg/kg, intravenously for more than 30 minutes, once every 3 weeks. Patients in the control group were iv administered with Aidi Injection on the basis of the control group, 50 mL/time, once daily. Both groups were treated for 6 weeks. The clinical efficacy of the two groups was observed. The quality of life score (FACT-L), KPS score, CD3⁺, CD4⁺, CD8⁺, CD4⁺/CD8⁺ indexes, interleukin-6 (IL-6), vascular endothelial growth factor (VEGF), transforming growth factor-β₁ (TGF-β₁), interferon-γ (IFN-γ) were compared between two groups. Results After treatment, the disease control rate of the treatment group was 83.33%, which was significantly higher than that of the control group (60.00%, P < 0.05). After treatment, the remission time of expectoration, chest tightness, chest pain, blood in sputum and other symptoms in the treatment group were significantly shorter than those in the control group (P < 0.05). After treatment, the FACT-L score and KPS score of the two groups were significantly higher than those before treatment (P< 0.05). After treatment, the FACT-L score and KPS score of the treatment group were higher than those of the control group (P < 0.05). After treatment, CD3⁺, CD4⁺, and CD4⁺/CD8⁺ indexes of the two groups were significantly increased compared with those before treatment, while CD8⁺ was significantly decreased (P < 0.05). After treatment, the improvement of T lymphocyte subsets in the treatment group was better than that in the control group (P < 0.05). After treatment, the levels of IL-6, VEGF and TGF-β1 in the two groups were significantly decreased, while IFN-γ was significantly increased (P < 0.05). After treatment, the improvement of serum inflammatory factors in treatment group was better than that in control group (P < 0.05). After treatment, the incidence of adverse reactions in the treatment group was 6.67%, which was significantly lower than 18.33% in the control group (P< 0.05). Conclusion Aidi Injection combined with pembrolizumab has a certain effect in treatment of advanced non-small cell lung cancer, and can improve the immune function of patients, effectively reduce the level of inflammatory factors, and improve the life quality of patients significantly, which is worthy of promotion.

R979.1